A4i is a patent pending, validated, digital therapeutic with a regulatory pathway for severe mental illness. A4i's first indication is outcomes improvements and relapse-risk identification in schizophrenia/psychosis spectrum illnesses. A joint venture between Canada's largest mental health teaching hospital (The Centre for Addiction and Mental Health) and The MEMOTEXT personalized digital therapeutics platform, A4i shows significant improvements in several outcome domains related to schizophrenia and psychoses recovery.

A4i Logo



Event details

Date: June 13 - 16, 2022

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


26 in total